Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pexidartinib - Daiichi Sankyo

Next Previous
X
Search
Drug Profile

Pexidartinib - Daiichi Sankyo

Alternative Names: Pexidartinib hydrochloride; Plexxikon 3397; PLX-3397; TURALIO

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Array BioPharma; AstraZeneca; Barbara Ann Karmanos Cancer Institute; Columbia University; Daiichi Sankyo Company; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Plexxikon; The Christie NHS Foundation Trust; University of California at San Francisco
  • Class 2 ring heterocyclic compounds; Antidementias; Antineoplastics; Fluorine compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony-stimulating factor receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant cell tumour of tendon sheath
  • Phase II Acral lentiginous melanoma; Glioblastoma; Malignant melanoma; Prostate cancer
  • Phase I/II Acute myeloid leukaemia; Breast cancer; Gastrointestinal stromal tumours; Leukaemia; Sarcoma; Solid tumours
  • No development reported Colorectal cancer; Pancreatic cancer
  • Discontinued Alzheimer's disease; Hodgkin's disease; Neurological disorders; Rheumatoid arthritis

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from phase-I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 13 Nov 2023 Daiichi Sankyo Company announces intention to submit regulatory applications for approval for Giant cell tumour of tendon sheath in some undisclosed countries/regions (Daiichi Sankyo Company pipeline, November 2023)
  • 22 Feb 2023 Pexidartinib is still in phase III trial for Giant cell tumour of tendon sheath in Japan (PO) (Daiichi Sankyo pipeline, February 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top